Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed

Context Therapeutics Inc.

Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.
Christopher Beck appointed SVP, Operations; previously VP of Program Management at Galera Therapeutics.
Mark Fletcher, Ph.D., appointed VP, R&D; previously VP of Product Development at Pharmaceutical Associates, Inc.
Appointments aim to advance lead candidate onapristone extended release (ONA-XR) in breast, ovarian, and endometrial cancers.
Rencher's retirement was planned, not due to disagreement; advisory role continues through October 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bill Rencher

Head of Chemistry Manufacturing Controls

CNTX · Context Therapeutics Inc.

Effective: 2022-01-01
Filed: January 5, 2022, 6:59 PM ET

As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bill Rencher retired as Head of Chemistry Manufacturing Controls at Context Therapeutics Inc..

Action: retired
Role: Head of Chemistry Manufacturing Controls

Exact text from the filing

As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.

View on SEC.gov

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-22-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.